Inoculum effect of CTX-M-15, OXA-48, and KPC-2 producing Klebsiella pneumoniae on meropenem and ceftazidime-avibactam efficacy.
Betalactamase inhibitors
Carbapenemase
Inoculum effect
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
13 Jan 2024
13 Jan 2024
Historique:
received:
21
10
2023
accepted:
04
01
2024
medline:
13
1
2024
pubmed:
13
1
2024
entrez:
12
1
2024
Statut:
aheadofprint
Résumé
The inoculum effect, characterized by diminished antibacterial activity at high bacterial inocula, is studied in the context of beta-lactam and beta-lactamase inhibitor combinations against beta-lactamase-producing Enterobacterales. The inhibition of ESBL + OXA-48 and KPC enzymes, in combination with ceftazidime, demonstrates encouraging results. In this study, 20 Klebsiella pneumoniae isolates were tested with different inocula (1-5 × 10
Identifiants
pubmed: 38216844
doi: 10.1007/s10096-024-04749-3
pii: 10.1007/s10096-024-04749-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Lenhard JR, Bulman ZP (2019) Inoculum effect of β-lactam antibiotics. J Antimicrob Chemoth 74:2825–2843. https://doi.org/10.1093/jac/dkz226
doi: 10.1093/jac/dkz226
Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M et al (2018) Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA 320:984. https://doi.org/10.1001/jama.2018.12163
doi: 10.1001/jama.2018.12163
pubmed: 30208454
pmcid: 6143100
Henderson A, Paterson DL, Chatfield MD, Tambyah PA, Lye DC, De PP et al (2020) Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study. Clin Infect Dis 73:e3842–e3850. https://doi.org/10.1093/cid/ciaa1479
doi: 10.1093/cid/ciaa1479
López-Cerero L, Picón E, Morillo C, Hernández JR, Docobo F, Pachón J et al (2010) Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum β-lactamase-producing and extended-spectrum β-lactamase-non-producing Escherichia coli isolates. Clin Microbiol Infect 16:132–136. https://doi.org/10.1111/j.1469-0691.2009.02893.x
doi: 10.1111/j.1469-0691.2009.02893.x
pubmed: 19614715
Adler A, Ben-Dalak M, Chmelnitsky I, Carmeli Y (2015) Effect of resistance mechanisms on the inoculum effect of carbapenem in Klebsiella pneumoniae isolates with borderline carbapenem resistance. Antimicrob Agents Chemother 59:5014–5017. https://doi.org/10.1128/aac.00533-15
doi: 10.1128/aac.00533-15
pubmed: 25987630
pmcid: 4505287
Sousa A, Pérez-Rodríguez MT, Soto A, Rodríguez L, Pérez-Landeiro A, Martínez-Lamas L et al (2018) Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother 73:3170–3175. https://doi.org/10.1093/jac/dky295
doi: 10.1093/jac/dky295
pubmed: 30099490
Castón JJ, Cano A, Pérez-Camacho I, Aguado JM, Carratalá J, Ramasco F et al (2022) Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study). J Antimicrob Chemother 77:1452–1460. https://doi.org/10.1093/jac/dkac049
doi: 10.1093/jac/dkac049
pubmed: 35187577
Pitart C, Solé M, Roca I, Fàbrega A, Vila J, Marco F (2011) First outbreak of a plasmid-mediated carbapenem-hydrolyzing OXA-48 β-lactamase in Klebsiella pneumoniae in Spain. Antimicrob Agents Chemother 55:4398–4401. https://doi.org/10.1128/aac.00329-11
doi: 10.1128/aac.00329-11
pubmed: 21746954
pmcid: 3165339
Solé M, Pitart C, Roca I, Fàbrega A, Salvador P, Muñoz L et al (2011) First description of an Escherichia coli strain producing NDM-1 carbapenemase in Spain. Antimicrob Agents Chemother 55:4402–4404. https://doi.org/10.1128/aac.00642-11
doi: 10.1128/aac.00642-11
pubmed: 21730115
pmcid: 3165357
Calbo E, Freixas N, Xercavins M, Riera M, Nicolás C, Monistrol O et al (2011) Foodborne nosocomial outbreak of SHV1 and CTX-M-15–producing Klebsiella pneumoniae: epidemiology and control. Clin Infect Dis 52:743–749. https://doi.org/10.1093/cid/ciq238
doi: 10.1093/cid/ciq238
pubmed: 21367727
(ESCMID) EC for AST (EUCAST) of the ES of CM and ID (2003) Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution. Clin Microbiol Infect 9:ix–xv. https://doi.org/10.1046/j.1469-0691.2003.00790.x
Docobo-Pérez F, López-Cerero L, López-Rojas R, Egea P, Domínguez-Herrera J, Rodríguez-Baño J et al (2013) Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model. Antimicrob Agents Chemother 57:2109–2113. https://doi.org/10.1128/aac.02190-12
doi: 10.1128/aac.02190-12
pubmed: 23439636
pmcid: 3632932
Cañada-García JE, Moure Z, Sola-Campoy PJ, Delgado-Valverde M, Cano ME, Gijón D et al (2022) CARB-ES-19 multicenter study of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli from all Spanish provinces reveals interregional spread of high-risk clones such as ST307/OXA-48 and ST512/KPC-3. Front Microbiol 13:918362. https://doi.org/10.3389/fmicb.2022.918362
doi: 10.3389/fmicb.2022.918362
pubmed: 35847090
pmcid: 9279682
Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, Duin D van, Clancy CJ (2023) Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin Infect Dis. https://doi.org/10.1093/cid/ciad428
Mizrahi A, Chat L, Danjean M, Mory C, Van JCN, de Ponfilly GP et al (2022) Inoculum effect of Enterobacterales co-expressing OXA-48 and CTX-M on the susceptibility to ceftazidime/avibactam and meropenem. Eur J Clin Microbiol 41:853–858. https://doi.org/10.1007/s10096-022-04430-7
doi: 10.1007/s10096-022-04430-7
Danjean M, Hobson CA, Gits-Muselli M, Courroux C, Monjault A, Bonacorsi S et al (2022) Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales. Clin Microbiol Infect 28:1503.e1-1503.e3. https://doi.org/10.1016/j.cmi.2022.06.018
doi: 10.1016/j.cmi.2022.06.018
pubmed: 35777602